Laska E M, Meisner M, Siegel C
Statistical Sciences and Epidemiology Division, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA.
Health Econ. 1997 Sep-Oct;6(5):497-504. doi: 10.1002/(sici)1099-1050(199709)6:5<497::aid-hec298>3.0.co;2-v.
We demonstrate that average cost-effectiveness ratios (CERs) play an important role in the evaluation of the cost-effectiveness of treatments. Criticisms of the usefulness of CERs derive mostly from the context of resource allocation under a constrained budget in which some decisions are based on incremental CERs. However, we show that in many cases, these decision rules are equivalent to decision rules on CERs. This follows for mutually exclusive treatments first, because a treatment is eliminated by extended dominance if and only if there is a mixed treatment with a smaller CER, where the mixing parameter lies in a certain interval. Second, after elimination of treatments by dominance and by extended dominance, resources can be allocated in order of increasing CERs. Moreover, the CER is a parameter that characterizes clinical and economical properties of a treatment independent of its comparators.
我们证明平均成本效益比(CERs)在治疗成本效益评估中发挥着重要作用。对CERs有用性的批评大多源于预算受限情况下的资源分配背景,在这种情况下,一些决策基于增量CERs。然而,我们表明,在许多情况下,这些决策规则等同于基于CERs的决策规则。首先,对于互斥治疗来说是这样,因为当且仅当存在一个CER更小的混合治疗(其中混合参数在某个区间内)时,一种治疗才会通过扩展优势被淘汰。其次,在通过优势和扩展优势淘汰治疗后,可以按照CERs递增的顺序分配资源。此外,CER是一个表征治疗的临床和经济特性的参数,与它的对照治疗无关。